CureVac, latest experimental coronavirus vaccine, proved just 47 percent effective amid spread of variants, preliminary analysis shows
The trial in 10 countries in Latin America and Europe will continue, and a final result is not expected until the end of June. The CureVac vaccine is of key importance to Europe, which has preordered 225 million doses.
View original article
Contributor: Carolyn Y. Johnson
